No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
Act-064992 |
- |
- |
- |
- |
[4] 85, 86, 88, 210 |
2 |
Administration of an ace-inhibitor or not |
- |
- |
- |
- |
[1] 210 |
3 |
Bosentan |
Bosentan |
D01227, D07538 |
[2] EDNRA, EDNRB |
[9] Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[9] 13, 41, 47, 51, 84, 85, 86, 88, 210 |
4 |
Macitentan |
Macitentan |
D10135 |
[2] EDNRA, EDNRB |
[9] Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[5] 51, 85, 86, 88, 210 |
5 |
Opsumit® |
- |
- |
- |
- |
[3] 86, 88, 210 |
6 |
Sildenafil |
Sildenafil |
D02229, D08514 |
[1] PDE5A |
[3] Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
[15] 6, 46, 50, 51, 85, 86, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
7 |
Tracleer |
Bosentan |
D01227, D07538 |
[2] EDNRA, EDNRB |
[9] Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[8] 13, 51, 84, 85, 86, 88, 210, 211 |